Overview | November 26, 2025
FFPE Multi-Omics for Precision Oncology Platforms
Get the Resource
Download NowPrecision oncology leaders have revolutionized genomic and transcriptomic profiling of FFPE tumors, yet they face the same strategic limitations:
- Lack of direct measures of target expression, pathway activity, or drug-target engagement. DNA/RNA data do not provide functional measures for understanding tumor biology and drug response.
- Missed opportunity for therapy-response prediction. Many tumors still respond due to downstream protein signaling or post-translational modifications (PTMs) that can only be seen via proteomic profiling of FFPE samples.
- Under-leveraged archives. Millions of FFPE tumors already profiled via genomics lack the proteomic dimension needed for full functional interpretation.
The result? Incomplete molecular insight for pharma partners and clinicians, and unrealized value from existing datasets and biobanks.
Sapient’s FFPE Proteomics extends molecular insights, adding the functional layer to genomics data already generated in archived tissue.
Our next-generation method enables deep proteomic profiling of FFPE tissues and tumors, directly quantifying >10,000 protein groups including phospho- and glyco-proteins, 200+ oncogenes, and 500+ approved drug targets in low input FFPE samples. This includes demonstrated detection across 100+ pathways such as EGFR, KRAS, p53, JAK3, and immune-checkpoint signaling.
By unlocking previously inaccessible protein insights from FFPE tissue, Sapient allows precision oncology platforms to enhance their partner offerings and expand monetization of their existing tumor datasets and biobanks.
Download the data sheet to see how Sapient’s FFPE Proteomics provides robust data that is complementary to existing genomics insights – delivering quantitative measures of pathway activity, PTMs, and isoforms.
Our workflows are optimized for discovery and clinical programs with hundreds to thousands of FFPE samples, enabling rapid retrospective proteomic re-analysis of tissue already collected with capacity to ensure rapid turnaround of results.
Discover new targets, biomarkers, and opportunities to enhance your pharma co-development opportunities with true FFPE-native proteomics that achieves proteome coverage comparable to fresh-frozen tissue, with exceptional reproducibility across replicates and FFPE sections.